Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in Patients Undergoing First Time CABG Surgery
A Phase II, Randomized, Single-Blind, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Hemolink[Tm] (o-Raffinose Cross-Linked Human Hemoglobin) in Subjects Undergoing Primary Coronary Artery Bypass Grafting Surgery
Sponsor: Hemosol
This PHASE2/PHASE3 trial investigates Cardiovascular Disease and is currently suspended. Hemosol leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Suspended PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Suspended PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Suspended PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Suspended PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Suspended PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hemosol
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Calgary, Canada, Chapel Hill, United States, Columbus, United States, Des Moines, United States, Detroit, United States, Durham, United States, Englewood, United States, Falls Church, United States, Houston, United States, Kingston, Canada and 15 more location s